FUM.LSE

Futura Medical

FUM.LSE, UK

Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company's lead product includes Eroxon, a topical gel for the treatment of erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women. The company operates in the United Kingdom, the European Union, the United States, and internationally. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.

https://www.futuramedical.com

Stock Price

GBp 0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
FUM.LSE
stock
FUM.LSE

Futura Medical plc Advances Healthcare Innovation Within FTSE AIM Framework Kalkine Media

Read more →
FUM.LSE
stock
FUM.LSE

Spreadex reduces stake in Futura Medical to 3.92% By Investing.com Investing.com South Africa

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

BUY

$

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

127.64

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-216.16 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-120.01 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-293.74 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Low

0.80

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Futura Medical

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2026-03-31

EPS Estimate

—

Latest Release

Date

2025-06-30

EPS Actual

-0.0217

EPS Estimate

0

EPS Difference

-0.0217

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1.5)
Momentum
Moderate Momentum(4)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(2)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-06-30)

Revenue

£ 0

Cost Of Revenue

£ 0

Gross Profit

£ 0

Operating Expenses

£ 0

Operating Income

£ 0

Interest Expense

£ 0

Pretax Income

£ 0

Net Income

£ 0

Income Tax Expense

£ 0

EBITDA

£ 0

Total Other Income Expense Net

£ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

£ 0

Short Term Investments

£ 0

Receivables

£ 0

Inventories

£ 0

Total Current Assets

£ 0

Property Plant Equipment

£ 0

Total Assets

£ 0

Payables

£ 0

Short Term Debt

£ 0

Long Term Debt

£ 0

Total Liabilities

£ 0

Equity

£ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

£ 0

Depreciation

£ 0

Change In Working Capital

£ 0

Cash From Operations

£ 0

Capital Expenditures

£ 0

Cash From Investing

£ 0

Cash From Financing

£ 0

Net Change In Cash

£ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.